

Supplementary Data

SUPPLEMENTARY TABLE S1. ASSOCIATIONS OF EXPOSURE TO INDIVIDUAL ARV MEDICATIONS
AT ANY TIME DURING PREGNANCY WITH NEUROLOGIC OUTCOMES

<i>Individual ARV medication</i>	<i>Overall^a N (%)</i>	<i>Ever had microcephaly</i>			<i>Ever had any neurologic conditions</i>		
		<i>Yes (%)^b</i>	<i>No (%)^b</i>	<i>p^c</i>	<i>Yes (%)^b</i>	<i>No (%)^b</i>	<i>p^c</i>
Nucleoside reverse transcriptase inhibitors (NRTIs)							
Abacavir							
Yes	35 (2.5)	2 (5.7)	33 (94.3)	1.00	2 (5.7)	33 (94.3)	0.77
No	1,365 (97.5)	103 (7.5)	1,262 (92.5)		132 (9.7)	1,233 (90.3)	
Didanosine							
Yes	73 (5.2)	5 (6.8)	68 (93.2)	1.00	5 (6.8)	68 (93.2)	0.54
No	1,327 (94.8)	100 (7.5)	1,227 (92.5)		129 (9.7)	1,198 (90.3)	
Emtricitabine							
Yes	4 (0.3)	0 (0.0)	4 (100.0)	1.00	0 (0.0)	4 (100.0)	1.00
No	1,396 (99.7)	105 (7.5)	1,291 (92.5)		134 (9.6)	1,262 (90.4)	
Lamivudine							
Yes	1,374 (98.1)	102 (7.4)	1,272 (92.6)	0.44	131 (9.5)	1,243 (90.5)	0.73
No	26 (1.9)	3 (11.5)	23 (88.5)		3 (11.5)	23 (88.5)	
Stavudine							
Yes	116 (8.3)	7 (6.0)	109 (94.0)	0.71	7 (6.0)	109 (94.0)	0.25
No	1,284 (91.7)	98 (7.6)	1,186 (92.4)		127 (9.9)	1,157 (90.1)	
Tenofovir							
Yes	42 (3.0)	1 (2.4)	41 (97.6)	0.36	3 (7.1)	39 (92.9)	0.79
No	1,358 (97.0)	104 (7.7)	1,254 (92.3)		131 (9.6)	1,227 (90.4)	
Zalcitabine							
Yes	2 (0.1)	1 (50.0)	1 (50.0)	0.14	1 (50.0)	1 (50.0)	0.18
No	1,398 (99.9)	104 (7.4)	1,294 (92.6)		133 (9.5)	1,265 (90.5)	
Zidovudine							
Yes	1,319 (94.2)	99 (7.5)	1,220 (92.5)	1.00	127 (9.6)	1,192 (90.4)	1.00
No	81 (5.8)	6 (7.4)	75 (92.6)		7 (8.6)	74 (91.4)	
Nonnucleoside reverse transcriptase inhibitors (NNRTIs)							
Efavirenz							
Yes	91 (6.5)	6 (6.6)	85 (93.4)	1.00	9 (9.9)	82 (90.1)	0.85
No	1,309 (93.5)	99 (7.6)	1,210 (92.4)		125 (9.5)	1,184 (90.5)	
Nevirapine							
Yes	503 (35.9)	45 (8.9)	458 (91.1)	0.12	53 (10.5)	450 (89.5)	0.36
No	897 (64.1)	60 (6.7)	837 (93.3)		81 (9.0)	816 (91.0)	
Protease inhibitors (PIs)							
Amprenavir							
Yes	3 (0.2)	0 (0.0)	3 (100.0)	1.00	0 (0.0)	3 (100.0)	1.00
No	1,397 (99.8)	105 (7.5)	1,292 (92.5)		134 (9.6)	1,263 (90.4)	
Atazanavir							
Yes	31 (2.2)	2 (6.5)	29 (93.5)	1.00	2 (6.5)	29 (93.5)	0.76
No	1,369 (97.8)	103 (7.5)	1,266 (92.5)		132 (9.6)	1,237 (90.4)	
Indinavir							
Yes	13 (0.9)	0 (0.0)	13 (100.0)	0.62	0 (0.0)	13 (100.0)	0.63
No	1,387 (99.1)	105 (7.6)	1,282 (92.4)		134 (9.7)	1,253 (90.3)	
Fosamprenavir							
Yes	2 (0.1)	1 (50.0)	1 (50.0)	0.14	1 (50.0)	1 (50.0)	0.18
No	1,398 (99.9)	104 (7.4)	1,294 (92.6)		133 (9.5)	1,265 (90.5)	
Lopinavir/ritonavir							
Yes	397 (28.4)	33 (8.3)	364 (91.7)	0.47	45 (11.3)	352 (88.7)	0.16
No	1,003 (71.6)	72 (7.2)	931 (92.8)		89 (8.9)	914 (91.1)	

(continued)

SUPPLEMENTARY TABLE S1. (CONTINUED)

<i>Individual ARV medication</i>	<i>Overall^a N (%)</i>	<i>Ever had microcephaly</i>			<i>Ever had any neurologic conditions</i>		
		<i>Yes (%)^b</i>	<i>No (%)^b</i>	<i>p^c</i>	<i>Yes (%)^b</i>	<i>No (%)^b</i>	<i>p^c</i>
Nelfinavir							
Yes	568 (40.6)	34 (6.0)	534 (94.0)	0.08	44 (7.8)	524 (92.3)	0.06
No	832 (59.4)	71 (8.5)	761 (91.5)		90 (10.8)	742 (89.2)	
Ritonavir							
Yes	2 (0.1)	0 (0.0)	2 (100.0)	1.00	0 (0.0)	2 (100.0)	1.00
No	1,398 (99.9)	105 (7.5)	1,293 (92.5)		134 (9.6)	1,264 (90.4)	
Saquinavir (hard and soft capsules)							
Yes	16 (1.1)	3 (18.8)	13 (81.3)	0.11	3 (18.8)	13 (81.3)	0.19
No	1,384 (98.9)	102 (7.4)	1,282 (92.6)		131 (9.5)	1,253 (90.5)	
Fusion inhibitors							
Enfuvirtide							
Yes	3 (0.2)	0 (0.0)	3 (100.0)	1.00	1 (33.3)	2 (66.7)	0.26
No	1,397 (99.8)	105 (7.5)	1,292 (92.5)		133 (9.5)	1,264 (90.5)	

^aColumn percentages are shown for overall use of individual ARVs.

^bRow percentages are shown for comparing the proportion with the outcome between those exposed and not exposed to individual ARVs.

^cp values for assessing the significance of the association of individual ARVs with the study outcomes are obtained using chi-square test or Fisher's exact test, where required, due to small cell size.

ARV, antiretroviral.